Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
Development of an effective home palliative care system
that adopts a multidisciplinary team approach
18590503
2006-2007 18-19
2008 20 5
---------------------------------------------------------------------------------- 1
---------------------------------------------------------------------- 1
---------------------------------------------------------------------- 2
---------------------------------------------------------------------- 3
---------------------------------------------------------------------- 4
---------------------------------------------------------------------- 5
-
---------------------------------------------------------------------- 6
---------------------------------------------------------------------- 7
---------------------------------------------------------------------- 8
---------------------------------------------------------------------- 9
---------------------------------------------------------------------- 9
---------------------------------------------------------------------- 11
---------------------------------------------------------------------- 11
---------------------------------------------------------------------- 12
---------------------------------------------------------------------- 13
---------------------------------------------------------------------- 18
---------------------------------------------------------------------- 21
1/24
2001 2008
2008 5
2/24
18 1,900,000 0 1,900,000
19 1,600,000 480,000 2,080,000
3,500,000 480,000 3,980,000
3/24
FAMCARE Scale 20
83
3.94
0.19 5 5
FAMCARE Scale
4 44
(1) (2) (3) (4) (5)
(6)FAMCARE Scale
4/24
This study looked at the team approach to home palliative care for terminal cancer patients that
has been pioneered in the city of Okayama over the past several years (Okayama palliative care
model). This team approach involves personnel from multiple disciplines. In this study, we first
clarified the appropriate conditions for smooth implementation of the model from a qualitative
study. Then, as the final outcome, we conducted a survey of satisfaction of the bereaved families.
The conditions shown to be appropriate for smooth implementation of the model were: (1)
regular study sessions and joint conferences with the participation of both the primary care and
palliative care teams, (2) adequate sharing of information, (3) understanding by the primary team
of the special type of care provided by the palliative care team, (4) appropriate sharing of roles
between the two teams, (5) respect of the primary care team, (6) emphasis on the central role of the
visiting nurse station, (7) creation of an emergency system, (8) use of care insurance, and (9)
cooperation with welfare professionals.
In the second part of the study, we first developed an official Japanese version of the
FAMCARE Scale, which is a scale developed in Australia to survey the satisfaction of the bereaved
families. A survey form consisting of 20 items from the FAMCARE Scale was then sent to 83
surviving family members of patients who had received care under the Okayama palliative care
model. The study plan was reviewed and approved by an ethics committee. The mean score for the
survey was 3.94 ± 0.19 points (out of a possible 5). Responses of “satisfied” or better were received by
more than 50% of respondents for nearly all items. The ratings were high for “pain relief,”
“responses by medical specialists to questions,” “physicians’ response to family requests to meet and
talk,” “physicians’ attention to symptoms,” and “time taken by primary physician for patient.” A
positive assessment was made for time spent and efforts made to respond to the desires of patients’
families following the conclusion of pain control prior to home palliative care. Conversely, issues
remain in items such as “always ensuring a bed for hospitalization.” Four factors were identified in
a factor analysis of the FAMCARE Scale: “adequate amount of information,” “attitude of medical
personnel,” “education and support system for families,” and “emergency responses.” Only 44% of
respondents were satisfied with nursing care, suggesting the need for environmental
improvements to ease the burden on families. The results of this study will be useful in developing
an appropriate model for a home palliative care system using a multidisciplinary team approach.
Key words (1)Home care, (2)Palliative care, (3)Multidisciplinary team approach,
(4)Qualitative research, (5)Satisfaction of the bereaved family, (6)FAMCARE Scale
5/24
1)
1
(Donabedian model2))
3)
6/24
2001
MSW OT
4)
1
PCU
1 5
7/24
1 2
6,7)
3)
3)
1
6,7)
8/24
6-8)
9/24
2001-2006
83
FAMCARE Scale
1
FAMCARE Scale 20
9)
5 5 4 3
2 1
9) (1)
information giving, (2) availability of care, (3) physical care,(4) psychosocial care
9)
10)
forward and
backward translation procedure 11) 2
2007 7 9 8 83 50 61.4%
67.9 26
7 5
28 22 57.1 FAMCARE
3.94 0.19 5
5
3 44
FAMCARE Scale
4
10/24
FAMCARE
1 1 2 3 4 5
2 1 2 3 4 5
3 1 2 3 4 5
4 1 2 3 4 5
5 1 2 3 4 5
6 1 2 3 4 5
7 1 2 3 4 5
8 1 2 3 4 5
9 1 2 3 4 5
10 1 2 3 4 5
11 1 2 3 4 5
12 1 2 3 4 5
13 1 2 3 4 5
14 1 2 3 4 5
15 1 2 3 4 5
16 1 2 3 4 5
17 1 2 3 4 5
18 1 2 3 4 5
19 1 2 3 4 5
20 1 2 3 4 5
FAMCARE Scale 10
11/24
FAMCARE Scale 5
44
2
3
12/24
1. 2004
2. Donabedian A: The definition of quality and approaches to its assessment. Health
Administration Press, Ann Arbor, 1980
3.
5(1):77-85, 2005
4. 2
2006 11 23
5.
10 2008 3 9
6.
14(1):30-40, 2006
7.
8(1):117-123, 2006
8.
11 2006 7
9. Kristjanson LJ: Validity and reliability testing of the FAMCARE Scale: Measuring
family satisfaction with advanced cancer care. Soc Sci Med 36(5):693-701, 1993
10. Ringdal GI, Jordhoy MS, Kaasa S: Measuring quality of palliative care:
Psychometric properties of the FAMCARE Scale. Qual Life REs 12:167-176, 2003
11. Shimozuma K, Yamaguchi M, Saito S, Kato T, Kikui K: Translation of the
FAMCARE Scale into Japanese: Report of Item History. 2008
13/24
2007-2008 19-20
1. Kuroi K, Shimozuma K, Taguchi T, Imai H, Yamashiro H, Ohsumi S, Saito S:
Evidence-based risk factors for seroma formation in breast cancer. Jpn J Clin Oncol
36(4):197-206, 2006
2. Ishikawa H, Saeki T, Otani T, Suzuki T, Shimozuma K, Nishino H, Fukuda S,
Morimoto K: Significance of garlic and its constituents in cancer and cardiovascular
disease. Aged garlic extract prevents a decline of NK cell number and activity in
patients with advanced cancer. J Nutr 136:816S-820S, 2006
3. Kuroi K, Shimozuma K, Taguchi T, Imai H, Yamashiro H, Ohsumi S, Saito S: Effect
of mechanical closure of dead space on seroma formation in breast surgery. Breast
Cancer 13(3):260-265, 2006
4.
- 8(1):117-123, 2006
5.
21(5):504-505, 2006
6.
quality of life 110(9):
710-716, 2006
7.
1 3
110(9): 703-709, 2006
8. David Cella, Sonya Eremenco,
QOL FACT-BRM
Biotherapy 20(2):217-222, 2006
9.
14(1):30-40, 2006
10. Hongo M, Kinoshita Y, Shimozuma K, Kumagai Y, Sawada M, Nii M: Psychometric
validation of the Japanese translation of the Quality of Life Reflux and Dyspepsia
14/24
questionnaire in patients with heartburn. J Gastroenterol 42(10): 807-815, 2007
11. Kurita M, Shimozuma K, Morita S, Fujiki Y, Ishizawa K, Eguchi H, Saito Y,
Ushiorozawa N, Wasada I, Ohashi Y, Eguchi K: Clinical validity of the Japanese
version of the Functional Assessment of Cancer Therapy-Anemia scale. Support
Care Cancer 15(1):1-6, 2007
12. Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K: The model-based
cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on
2-year follow-up HERA trial data. Breast Cancer Res Treat 2007(online)
13. Shimozuma K: Assessment of quality breast cancer care: current status and
unsolved problems. Breast Cancer 14(1):59, 2007 (Editorial)
14. Shimozuma K, Imai H, Kuroi K, Ohsumi S, Ono M: Recent topics of health
outcomes research in oncology. Breast Cancer 14(1):60-65, 2007
15. Ohsumi S, Shimozuma K, Kuroi K, Ono M, Imai H: Quality of life of breast cancer
patients and types of surgery for breast cancer – Current status and unresolved
issues. Breast Cancer 14(1):66-73, 2007
16. Kuroi K, Shimozuma K, Ohsumi S, Imai H, Ono M: Current status of health
outcome assessment of medical treatment in breast cancer. Breast Cancer
14(1):74-80, 2007
17. Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K: Economic evaluation of the
prevention and treatment of breast cancer - present status and open issues. Breast
Cancer 14(1):81-87, 2007
18. Ono M, Imai H, Kuroi K, Ohsumi S, Shimozuma K: Quality of Japanese health care
evaluated as hospital functions. Breast Cancer 14(1):88-91, 2007
19.
1 quality of life
111(4):315-321, 2007
20. 2
QOL
59-64, 2007
21. QOL
20 5 Junior 10 465:31-34,
2007
22. QOL ?
20 6 Junior 10 466:35-38,
2007
23.
15/24
20 7 Junior 11 467:29-32,
2007
24. QOL QOL QOL
33(12):1742-1746, 2007
25.
9(2):131-137, 2007
26. QOL 65(1): 157-163, 2007
1. Takei H, Ohsumi S, Shimozuma K, Ohashi Y, Fujiki Y, Suemasu K, Hozumi Y:
Health-related quality-of-life and psychological distress of breast cancer patients
after surgery during phase III randomized trial comparing tamoxifen, exemestane,
and anastrozole: N-SAS BC 04. The 29th Annual San Antonio Breast Cancer
Symposium, Dec. 14 - 17, 2006
2. Fukuda T, Ohsumi S, Mukai H, Morita S, Imai H, Watanabe T, Shimozuma K,
Ohashi Y: Quality of life of patients receiving adjuvant chemotherapies for breast
cancer in Japan. ISPOR Europe, 2006
3. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S,
Makino H, Watanabe T, Hausheer FH: Assessment and quantification of
taxane-induced neurotoxicity in a phase III randomized trial of patients with breast
cancer (AC followed by PAC/DOC vs. PAC/DOC alone): N-SAS BC 02. J Clin Oncol
24(18S):473s, 2006
4. Fukuda, T, Mouri M, Hirose N, Ohsumi S, Mukai H, Morita S, Imai H, Watanabe T,
Shimozuma K, Ohashi Y: Methods of cost data collection for pharmacoeconomic
study along with a clinical trial in Japan. ISPOR 2nd Asia-Pacific Conference.
March 5-7, 2006 Shanghai, China
5.
14 2006 7 7
6.
RCT
QOL NSASBC03 14 2006 7 7
7.
Patient Neurotoxicity Questionnaire: PNQ
16/24
14 2006 7 7
8.
Frederick Hausheer:
14 2006 7 6
9.
trastuzumab 14 2006 7 6
10.
14 2006 7 6
11.
11
2006 6 23 24
12.
1 Quality of Life(QOL). 109
2006 4 13 16
13. Takehara M, Ohsumi S, Takei H, Shimozuma K, Suemasu K, Hozumi Y:
Health-related quality of life and psychological distress in Japanese patients with
breast cancer treated with tamoxifen, exemestane or anastrozole for adjuvant
therapy: a phase III randomized study of National Surgical Adjuvant Study of
Breast Cancer (N-SAS BC) 04. 30th San Antonio Breast Cancer Symposium Dec.
13-16, 2007 San Antonio, U.S.A. 2088
14. Saito S, Shimozuma K, Ohashi Y, Fukuda T, Fukui N, Mouri M, Kuroi K: Basic
attitude to use of generic anti-cancer drugs for breast cancer treatment in Japan.
ISPOR 10th Annual European Congress, Dublin Ireland, Oct. 20-23, 2007
15. Shimozuma K, Yamaguchi T, Fujita K, Yuzawa M, Suzukamo Y, Takahashi N,
Takahashi K, Morita S, Fukuhara S: Response shift in a randomized controlled
trial of low vision care for patients with age-related maculopathy. 14th Annual
Conference of the International Quality of Life Research, Toronto, Ontario, Canada,
Oct 10-13, 2007
16. Kuroi K, Shimozuma K, Ohashi Y, Takeuchi A, Aranisnishi T, Morita S, Ohsumi S,
Makino H, Watanabe T, Hausheer FH: Prospective assessment of
chemotherapy-induced neurotoxicity in breast cancer (HOR 02) and questionnaire
survey of physician‘s perspectives. 2007 ASCO Annual Meeting, Chicago, June 1-5,
2007
17. Makino H, Shimozuma K, Watanabe T, Ohashi Y, Katsumata N, Sonoo H,
Takashima S, N-SAS BC: Comparison of quality of life (QOL) between adjuvant
17/24
cyclophosphamide, methotrexate, and fluorouracil (CMF) and oral uracil/tegafur in
high-risk, node-negative breast cancer - A phase III randomized trial (N-SAS BC
01). 2007 St. Gallen Breast Cancer Conference, St. Gallen, March 14-17, 2007
18.
Xeloda 45 2007 10 25
19.
45 2007 10 24
20.
QOL 15
2007 6 30
21.
10 2008 3 9
1. 2006
2006 pp16-32
2. 2
2006
7 pp26-32
3. QOL 3
2006 pp78
4. 1
2006 pp19-32
5. 13 QOL
2007 11 pp86-89
18/24
1.
14(1):30-40, 2006
2.
29(1):83-88, 2006
3.
8(1):117-123, 2006
4.
2007
5.
31-41, 2007
6.
11(8):793-797, 2006
7.
11(10):970-973, 2006
8.
11(11):1042-1046, 2006
9.
11(12):1126-1129, 2006
10.
12(1):50-55, 2007
11. 23 5
,468g
12(2):138-142, 2007
12.
19/24
12(3):230-235, 2007
1.
2006 6 11 pp99
2.
2006 10 30 29(2) 30
pp195
3.
CAI
2007 3 20 pp54
4. Yamaguchi M, Yokono M, Saito S, Shimizu ME, Okamoto T: Treatment of severely
handicapped newborns in Japan: Ethical dilemmas experienced by physicians with
the parents. 2007 10 9th American Society for Bioethics and Humanities
5. Yokono M, Shimizu ME, Yamaguchi M, Saito S, Okamoto T: Treatment of severely
handicapped newborns in Japan: Ethical dilemmas and the law. 2007 10 9th
American Society for Bioethics and Humanities
6. Saito S, Yamaguchi M, Shimizu ME, Yokono M, Okamoto T: Treatment of severely
handicapped newborns in Japan: Differences in the perspectives of the different
pediatric and obstetric medical specialties. 2007 10 9th American Society for
Bioethics and Humanities
7.
10 2008 3 9
1.
7 2 2006
4 pp66-70
2.
20/24
2
EBN 2006 5 pp28-37
3. 6
11
2007 12 pp231-351
21/24
1.
11(1):52-59, 2006
2. 55:71-86,
2006
3.
14 1 :30-40, 2006
4.
TJ-41 67(3):568-574, 2006
5.
- 8(1):117-123, 2006
6.
21(5):504-505, 2006
7.
40(4):69-72, 2006
8.
Toll-like receptor4 HGF GI
Research 14(2):150-158, 2006
9. Katsuno G, Takahashi HK, Iwagaki H, Sugita S, Mori S, Saito S, Yoshino T,
Nishibori M, Tanaka N: The effect of ciprofloxacin on CD14 and toll-like
receptor-4 expression on human monocytes. 25(3):247-253, 2006
10. Katsuno G, Takahashi HK, Iwagaki H, Mizuno K, Yagi T, Mori S, Saito S,
Yoshino T, Nishibori M, Tanaka N: The immunosuppressive effects of
ciprofloxacin during human mixed lymphocyte reaction. Clin Immunol
119(1):110-119, 2006
11. Kuroi K, Shimozuma K, Taguchi T, Imai H, Yamashiro H, Ohsumi S, Saito S:
Evidence-based risk factors for seroma formation in breast surgery Jpn J Clin
Oncol 36:197-206, 2006
12. Kuroi K, Shimozuma K, Katsumasa Kuroi, Taguchi T, Imai H, Yamashiro H,
Ohsumi S, Saito S: Effect of mechanical closure of dead space on seroma
formation after breast surgery. Breast Cancer 13:206-265, 2006
22/24
13.
29(1):89-94, 2006
14.
12(3):230-235, 2007
15. 9(2):31-38,2007
16.
LPS
CD14,TLR-4 4(2):149-156, 2007
17.
12(5):408-414, 2007
18.
2
12(6):508-513, 2007
19. , ,
Palliat Care Res 2(1):112-116, 2007
20. Saito S, Shimozuma K, Ohashi Y, Fukuda T, Fukui N, Mouri M, Kuroi K: Basic
attitude to use of generic anti-cancer drugs for breast cancer treatment in Japan.
Value in Health 10(6) A339, 2007
1.
12 6
2.
: LPS receptor
(CD14/TLR-4) 106
2006 4
3.
11 2006 7
4.
14 2006 7
5.
23/24
44 2006 10
6.
30 2006 11
7.
30 2006
11
8.
18
2006 11
9.
45 2007 10
10.
31
2007 11
11. 42
2007 11
12. Saito S, Yamaguchi M, Shimizu ME, Yokono M, Okamoto T: Treatment of
severely handicapped newborns in Japan: Differences in the perspective of the
different pediatric an obstetric medical specialties. American Society for
Bioethics & Humanities. October 2007 Washington DC, USA
13. Yamaguchi M, Yokono M, Saito S, Shimizu ME, Okamoto T: Treatment of
severely handicapped newborns in Japan: Ethical dilemmas experienced by
physicians with the parents. American Society for Bioethics & Humanities.
October 2007 Washington DC, USA
14. Shimizu ME, Yokono M, Yamaguchi M, Saito S, Okamoto T: Treatment of
severely handicapped newborns in Japan: Ethical dilemmas and the law.
American Society for Bioethics & Humanities. October 2007 Washington DC,
USA
15. Saito S, Shimozuma K, Fukuda T, Ohashi Y, Fukui N, Mouri M, Kuroi K: Basic
Attitude to Use of Generic Anti-Cancer Drugs for Breast Cancer Treatment in
Japan. International Society for Pharmacoeconomics and Outcomes Research,
10th Annual European Congress. October 2007 Dublin, Ireland
16.
24/24
10 2008 3 9
72
2007, pp45-61